Archives: 上海夜网TZ

Willian or Coutinho? Martin Keown sends transfer advice to Mikel Arteta

October 18, 2020 | By admin | No Comments | Filed in: iuxgjddtb.

first_imgKeown gave his verdict on the duo (Picture: Action Foto Sport/NurPhoto via Getty Images)‘I think that’s a fantastic bit of business. I have always been a real admirer of Willian.‘When I saw what he has been doing this year at Chelsea with his free-kicks and penalties, he’s so realible.‘He has had his misfortunes with [Eden] Hazard being there. Sometimes he has had to play second-fiddle. Now he is fighting for a place with [Christian] Pulisic.More: Arsenal FCArsenal flop Denis Suarez delivers verdict on Thomas Partey and Lucas Torreira movesThomas Partey debut? Ian Wright picks his Arsenal starting XI vs Manchester CityArsene Wenger explains why Mikel Arteta is ‘lucky’ to be managing Arsenal‘I know there is a discussion over two or three years [contract], but I think he would be a really good acquisition for Arsenal.‘He comes in with a wealth of experience and I like his work ethic.‘He is someone who will always give you 100% and the right type of player to go into what is a really young Arsenal dressing room.’Who would be the better signing for Arsenal?Coutinho0%Willian0%Share your resultsShare your resultsTweet your resultsFollow Metro Sport across our social channels, on Facebook, Twitter and Instagram.For more stories like this, check our sport page. Comment Metro Sport ReporterSaturday 8 Aug 2020 1:06 pmShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link6.1kShares Advertisement Coutinho and Willian have both been linked to Arsenal (Picture: Getty)Martin Keown believes Arsenal will be better off signing Willian rather than Philippe Coutinho. The Gunners have been heavily linked with moves for both Brazilians, with Chelsea star Willian seemingly on the verge of moving to the Emirates on a free transfer. It’s been suggested that Coutinho could also move to north London on loan next season, with Bayern Munich not planning on signing the Barcelona man on a permanent basis. But Keown feels Willian is the superior signing and thinks he should be the priority if it comes down to a choice between the duo.ADVERTISEMENT‘Coutinho has been linked with virtually everybody and seems, if I am honest, a bit unsettled,’ Keown told The Mirror.AdvertisementAdvertisement‘I think Willian is a safer bet. He’s in the capital, he knows the Premier League very well and he’s a top performer. I think it’s a huge loss for Chelsea. Willian or Coutinho? Martin Keown sends transfer advice to Mikel Arteta Advertisementlast_img read more

Tags: , , , , , , , , , , ,

These platelet decoys could prevent blood clots without spreading cancer

July 20, 2019 | By admin | Comments Off on These platelet decoys could prevent blood clots without spreading cancer | Filed in: Uncategorized.

first_imgPlatelet decoys (surrounded here by collagen fibers) could help us better understand platelet biology and potentially be a treatment for some patients. Sign up for our daily newsletter Get more great content like this delivered right to you! Country By Jennifer Couzin-FrankelFeb. 13, 2019 , 2:00 PM Click to view the privacy policy. Required fields are indicated by an asterisk (*) Anna Waterhouse, Anne-Laure Papa, Donald Ingber/Wyss Institute at Harvard Like Jekyll and Hyde, the platelets in your blood are both good and evil. These specialized blood cells halt bleeding and help reconstruct injured tissue. But they can also cause dangerous blood clots and protect cancer cells as they travel from one site to another. Now, a team of bioengineers has taken the first step toward tipping this balance to the light side by creating “platelet decoys,” which in the lab mimic the real thing without causing clots.“It’s a really fascinating sort of drug approach,” says Susan Smyth, chief of cardiology at the University of Kentucky in Lexington, who was not involved with the study.Platelets are more harmful in some people than in others. Those at high risk of blood clots—such as someone who’s recently had a heart attack or a blood clot in their lung—are often put on antiplatelet drugs. But if people on these medications need surgery or get into a serious accident, they’re at high risk of bleeding. In patients with cancer, previous work has found that platelets bind to cancer cells and, by building something of a clot-wall around the cells, cushion them as they journey through the bloodstream and seed elsewhere in the body.  center_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Email These platelet ‘decoys’ could prevent blood clots without spreading cancer It was this dance between platelets and cancer cells that first attracted Anne-Laure Papa, a bioengineer at George Washington University in Washington, D.C. In 2014, she and her colleagues reported that inhibiting platelets before chemotherapy in animals reduced tumor growth. Papa then turned her attention to how platelets drive metastasis. “Can we design something that could interfere with” platelets’ protection of cancer cells, she wondered, making it harder for tumors to crop up elsewhere? She envisioned a “platelet decoy,” a structure that could compete with platelets in the bloodstream. Cancer cells could bind to the decoys, but they wouldn’t benefit from safe travel in the same way they do with real platelets.At the time, Papa was working in the lab of cell biologist and bioengineer Donald Ingber, who directs the Wyss Institute at Harvard University in Boston. He suggested starting with a strategy he’d used in the past: Immersing cells in chemicals that strip away parts of their membrane and much of their contents. “You’re left with these little whiffle balls,” Ingber says. If the same was done to platelets, the stripped-down clot-stoppers could still bind to cells and “take up spaces where the normal platelets would go,” Ingber reasoned. But unlike real platelets, they wouldn’t cause clotting.To test the idea, the researchers added their stripped-down platelets to healthy platelets in a petri dish. They impaired the platelets’ natural clotting mechanism. On a “lab on a chip” that mimics the kind of clotting that can cause heart attacks, the decoys also blocked clotting when mixed with real human platelets.Next, the group tested its decoys in rabbits. The researchers used a suture to injure part of the animal’s carotid artery, causing blood clots to form there. The team then infused platelets, decoys, or a mixture. Adding decoys, even when combined with normal platelets, prevented blood clots from growing and migrating into the circulation. Studies in mice found that when they were injected at the same time as platelets and cancer cells, platelet decoys made with human cells could prevent the spread of breast cancer, the team reports today in Science Translational Medicine.Smyth says one of the problems she and other cardiologists run into is that the body takes a week or more to clear some antiplatelet drugs. This means that patients needing surgery must stop taking medication about 5 to 10 days beforehand—putting them at risk of clots during that time. Papa’s and Ingber’s work suggests that unlike antiplatelet drugs, it’s easy to quickly eliminate the effect of decoys from the body by administering real platelets. This means the decoys may be useful in that 10-day period for patients who can’t be on the drugs because of impending surgery, but who are also at risk of blood clots without those drugs.But what if the stripped-down platelets disappear too quickly? If their half-life is just a few minutes, their usefulness in patients will be limited, says Mortimer Poncz, a pediatric hematologist at Children’s Hospital of Philadelphia in Pennsylvania who is also working on strategies to combat the negative effects of platelets. Papa says how long the decoys endure, and whether they might be coaxed to circulate even longer than platelets, is something she plans to study.Offering these decoys to patients is a long way off, but experts agree they could prove useful as a research tool more quickly. “There’s so much to learn,” says Jason Katz, a cardiologist and critical care physician at the University of North Carolina in Chapel Hill. Papa agrees, suggesting that biologists might use the decoys in experiments to untangle how platelets bind to different cells.*Clarification, 13 February, 5:30 p.m.: This item has been updated to clarify how long it takes the body to clear antiplatelet drugs.last_img read more

Tags: , , , , , , , , ,